Nektar Therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. Nektar also partners with the top biopharmaceutical companies to bring new products to market. To date, Nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.

News Jul 28, 2010 Nektar Therapeutics Reports Second Quarter 2010 Financial Results » Jul 21, 2010 Nektar to Announce Financial Results for the Second Quarter of 2010 On Wednesday, July 28, 2010, After Close of U.S.-Based Financial Markets » Jul 6, 2010 NKTR-102 Demonstrates Superior Activity to Irinotecan in Nonclinical Studies Presented at ESMO 12th World Congress on Gastrointestinal Cancer » Jun 24, 2010 Nektar Announces Dosing of First Patients in Phase 1 Clinical Study of NKTR-102 in Combination With 5-Fluorouracil/Leucovorin »

Contact Nektar investor relations Jennifer Ruddock Vice President of Investor Relations and Corporate Affairs 650-631-4954 Contact